FBT ETF Research - First Trust Amex Biotech Index Fund

First Trust Amex Biotech Index Fund (fbt)

Last Updated by Anonymous | Update This Page Now

►Summary | Add New ETF | Feedback

Short Term Rating Stock Ratings Help

Asset Allocation (% of Port)

US Stocks
Non-US Stocks

Geographic Allocation (% of Port)

North America
South America
Australia + Pacific Islands
Long Term Rating Stock Ratings Help


SWOT Statistics

Strengths + Opportunities = 109

Threats + Weaknesses = 81

When strengths & opportunities substantially exceed threats & weaknesses an investment in the fbt ETF has great long term potential.

ETF Description Update

First Trust Amex Biotech (FBT) Description: FBT is an exchange trading fund (ETF), which is a security that tracks a basket of assets, but trades like a stock. FBT exchange trading fund (ETF) tracks the SE Arca Biotechnology; the nyse arca biotechnology index is an equal dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services First Trust Amex Biotech (FBT) falls under the Health & Biotech Equities category. FBT's dividend yield is roughly 0%, it has an expense ratio of 0.6%, and is in the equity ETF asset class. First Trust Amex Biotech (FBT) focuses its investments in the U.S. region of the world. FBT does not use leverage and FBT's performance is meant to match its benchmark. The FBT ETF belongs to the Health & Biotech sector. An investor can find FBT's top holdings, fundamental analysis, and fund ratings on the left side of the screen. The right side features FBT's technical analysis chart and long term fund potential. Long term and short term buy ratings indicate our highest possible valuation rating. Click here for additional information on First Trust ETF funds or see the ETF research & analysis home page to start.

Portfolio Strategy Update

Be the first to explain First Trust Amex Biotech Index Fund (FBT)'s strategy.

Performance Analysis Update